

SINGAPORE
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

Proteomics International Laboratories Ltd (PILL)

PILL [ASX: PIQ] is a medtech company applying its disruptive technology platform to study the structure and function of proteins, focusing on the discovery and commercialisation of new diagnostic biomarkers.

PILL has developed a unique predictive test for diabetic kidney disease – known as PromarkerD, and has signed its first million-dollar licensing deal for the US Territory of Puerto Rico. PILL is currently expanding its diagnostics portfolio using the Promarker™ discovery platform, and is investigating protein ‘fingerprints’ to diagnose other chronic conditions with unmet medical need (including endometriosis and mesothelioma).

PILL operates in three integrated areas unified by its proprietary proteomics-based technology platform: *Diagnostics*, *Peptide drug discovery* and *Analytical services* (specialising in biosimilars and biologics). This sustainable business model merges blue sky opportunities with cash flow, using revenue generated from analytical services to fund pioneering research into next generation diagnostic tests and drug discovery.